Hematology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared advice for young scientists entering the cell and gene therapy field.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the unpredictability of "living drugs" in the human body and the ongoing development of understanding.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on how streamlined collaboration can help move therapies to patients faster.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed strategies used to streamline development in cell and gene therapy.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the major friction points in cell and gene therapy development and uptake.

Review top news and interview highlights from the week ending October 24, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on major moments in the past 25 years of cell and gene therapy research.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 17, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 10, 2025.

Verismo emphasized that the milestone strengthens its relationship with the Institute for Follicular Lymphoma Innovation.

AVB-114 previously received fast track designation from the FDA in February of this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The PDUFA target action date for the BLA has been set at April 6, 2026.

The company cited strategic prioritization as the reason for its decision.

Review top news and interview highlights from the week ending October 3, 2025.

UB-VV111 is currently being evaluated in a phase 1 clinical trial for adult patients with R/R CD19+ B-cell malignancies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In observance of Rare Cancer Day, held annually on September 30, catch up on the past few months’ news related to cell therapy for such indications.

Review top news and interview highlights from the week ending September 26, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending September 19, 2025.

The trial, which is taking place in the United States, is expected to enroll 40 patients in total.